Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients
Metadatos
Afficher la notice complèteAuteur
González Salvatierra, Sheila; Martínez Heredia, Luis; Muñoz Torres, Manuel Eduardo; Riquelme Gallego, BlancaEditorial
MDPI
Materia
Biomarker Diabetic kidney disease Kidney function impairment Type 2 diabetes Osteoglycin
Date
2021Referencia bibliográfica
González-Salvatierra, S.; García-Fontana, C.; Andújar-Vera, F.; Grau-Perales, A.B.; Martínez-Heredia, L.; Avilés-Pérez, M.D.; Hayón-Ponce, M.; Iglesias-Baena, I.; Riquelme-Gallego, B.; Muñoz-Torres, M.; et al. Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients. J. Clin. Med. 2021, 10, 2209. https://doi.org/jcm10102209
Patrocinador
Junta de Andalucía grants (PI-0207-2016 and PI0268-2019); Instituto de Salud Carlos III grants (PI18-00803 and PI18-01235); European Regional Development Fund (FEDER); Instituto de Salud Carlos III (FI19/00118; CD20/00022)Résumé
Osteoglycin (OGN) could be a biomarker of mild kidney function impairment in type 2 diabetes (T2D). Our study aimed to determine the association between serum OGN and impaired kidney
function risk in T2D patients and to analyze its potential role as an estimator of kidney disturbances
in this population. This cross-sectional study included 147 T2D patients (65 ± 8 years, 58.5% males),
and 75 healthy controls (63 ± 10 years, 36% males). Circulating OGN levels were determined by
ELISA. Linear regression modeling was performed to determine the variables influencing circulating
OGN, and an ROC curve was plotted to assess the usefulness of OGN as an estimator of diabetic
kidney disease risk. Circulating OGN was significantly increased in T2D patients compared to
controls (18.41 (14.45–23.27) ng/mL vs. 8.74 (7.03–12.35) ng/mL; p < 0.001). We found a progressive
increase in serum OGN according to the severity of kidney impairment in T2D patients (normal
kidney function: 16.14 (12.13–20.48) ng/mL; mildly impaired kidney function: 19.15 (15.78–25.90)
ng/mL; moderate impaired kidney function: 21.80 (15.06–29.22) ng/mL; p = 0.006). Circulating OGN
was an independent estimator of mildly impaired kidney function risk in T2D patients. We suggest
that serum OGN could act as an albuminuria-independent biomarker of incipient kidney dysfunction
in T2D patients.